JP2020508655A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508655A5 JP2020508655A5 JP2019544812A JP2019544812A JP2020508655A5 JP 2020508655 A5 JP2020508655 A5 JP 2020508655A5 JP 2019544812 A JP2019544812 A JP 2019544812A JP 2019544812 A JP2019544812 A JP 2019544812A JP 2020508655 A5 JP2020508655 A5 JP 2020508655A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- substantially similar
- light chain
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 21
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 21
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 20
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 20
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 20
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 6
- 102000043321 human CTLA4 Human genes 0.000 claims 6
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461560P | 2017-02-21 | 2017-02-21 | |
| US62/461,560 | 2017-02-21 | ||
| PCT/US2018/012545 WO2018156250A1 (en) | 2017-02-21 | 2018-01-05 | Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508655A JP2020508655A (ja) | 2020-03-26 |
| JP2020508655A5 true JP2020508655A5 (https=) | 2021-02-12 |
| JP7165995B2 JP7165995B2 (ja) | 2022-11-07 |
Family
ID=63254023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544812A Active JP7165995B2 (ja) | 2017-02-21 | 2018-01-05 | 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11319372B2 (https=) |
| EP (1) | EP3585430A4 (https=) |
| JP (1) | JP7165995B2 (https=) |
| CN (1) | CN110545844A (https=) |
| WO (1) | WO2018156250A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| MY198194A (en) | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
| MX2018013386A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| DK3551660T5 (da) | 2016-12-07 | 2024-09-02 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| KR102784294B1 (ko) | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| JP7173993B2 (ja) | 2017-05-19 | 2022-11-17 | ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド | 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体 |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210108978A (ko) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
| CA3122773A1 (en) | 2018-12-26 | 2020-07-02 | Xilio Development, Inc. | Anti-ctla4 antibodies and methods of use thereof |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| WO2020163817A1 (en) * | 2019-02-08 | 2020-08-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| WO2021170750A1 (en) | 2020-02-28 | 2021-09-02 | Orega Biotech | Combination therapies based on ctla4 and il-17b inhibitors |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| WO2021250594A1 (en) | 2020-06-11 | 2021-12-16 | Nantbio, Inc. | Anti-ctla4 monoclonal antibodies and chimeric antigen receptors |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| CN113244389B (zh) * | 2021-07-06 | 2021-09-17 | 诺赛联合(北京)生物医学科技有限公司 | 一种TILs细胞制备方法及在肿瘤治疗的用途 |
| WO2023134771A1 (zh) * | 2022-01-17 | 2023-07-20 | 上海君实生物医药科技股份有限公司 | 抗ctla-4抗体药物组合物及其用途 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| EP4687991A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2025140296A1 (zh) * | 2023-12-26 | 2025-07-03 | 上海宏成药业有限公司 | 抗dll3抗体或其抗原结合片段及其用途 |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026012032A1 (en) * | 2024-07-10 | 2026-01-15 | Wuxi Biologics (Shanghai) Co., Ltd. | Antibodies against integrin and uses thereof |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| US7494779B2 (en) * | 2004-06-14 | 2009-02-24 | Li-Te Chin | Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist |
| EP2749571A3 (en) | 2006-01-10 | 2014-08-13 | ZymoGenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists |
| WO2009100140A1 (en) | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| CN101628940B (zh) * | 2008-07-15 | 2011-11-23 | 中国科学院生物物理研究所 | 一种单克隆抗体及其应用 |
| WO2010014784A2 (en) * | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CN104292334B (zh) * | 2014-04-25 | 2018-11-27 | 河南省健康伟业生物医药研究股份有限公司 | 一种全人源抗ctla-4单克隆抗体、制备方法及应用 |
| EP3256165B1 (en) | 2015-02-13 | 2021-07-14 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind ctla4 |
| MA53355A (fr) | 2015-05-29 | 2022-03-16 | Agenus Inc | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
-
2018
- 2018-01-05 JP JP2019544812A patent/JP7165995B2/ja active Active
- 2018-01-05 WO PCT/US2018/012545 patent/WO2018156250A1/en not_active Ceased
- 2018-01-05 CN CN201880026480.5A patent/CN110545844A/zh active Pending
- 2018-01-05 EP EP18757386.0A patent/EP3585430A4/en not_active Withdrawn
- 2018-01-05 US US16/487,330 patent/US11319372B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508655A5 (https=) | ||
| AU2019243665B2 (en) | Multivalent antibody | |
| JP2018522888A5 (https=) | ||
| JP2017504578A5 (https=) | ||
| JP2012525829A5 (https=) | ||
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2013545738A5 (https=) | ||
| JP2019524693A5 (https=) | ||
| JP2017526370A5 (https=) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| JP2023551027A5 (https=) | ||
| EP3634998B1 (en) | Anti-cd3 epsilon antibodies | |
| HRP20240415T1 (hr) | Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba | |
| JP2020514277A5 (https=) | ||
| EP3684802A1 (en) | Novel stable antibody variable domain framework combinations | |
| US20220340677A1 (en) | Split intein and preparation method for recombinant polypeptide using the same | |
| HRP20131215T1 (hr) | Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope | |
| JP2013545455A5 (https=) | ||
| RU2018137110A (ru) | Антитела против psma и их применение | |
| JP2022545647A5 (https=) | ||
| RU2013142600A (ru) | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы | |
| SI2699264T1 (en) | Antibodies and other molecules that bind b7-h1 and pd-1 | |
| RU2021111382A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| IL280487B2 (en) | Anti-mica/b antibodies that block mica/b shedding and methods of use |